Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype

被引：0

作者：

Marotta, G ^{[1
]}

Bigazzi, C ^{[1
]}

Bocchia, M ^{[1
]}

Forconi, F ^{[1
]}

Lauria, F ^{[1
]}

机构：

[1] Univ Siena, A Sclavo Hosp, Div Hematol, I-53100 Siena, Italy

来源：

HAEMATOLOGICA | 1998年 / 83卷 / 09期

关键词：

non Hodgkin lymphoma; ProMACE-CytaBOM regimen; long-term follow-up;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Long-lasting results achieved in 54 patients with aggressive non-Hodgkin lymphoma treated with Pro-MACE-CytaBOM regimen were evaluated. Twenty-four out of 54 (45%) patients achieved a complete remission and 13 of them are still in continuous remission with a median survival of 53.5 months. Interestingly, in 16 patients with intermediate grade histology we obtained an overall response rate of 100%.

引用

页码：853 / 854

页数：2

共 50 条

[31] Long term follow-up of CEOP in the treatment of HIV related non-Hodgkin's lymphoma (NHL)
Davis, AJ
Goldstein, D
Milliken, S
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1998, 28 (01): : 28 - 32
[32] Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): long-term follow-up and analysis of prognostic factors
AP Rapoport
R Lifton
LS Constine
RE Duerst
CN Abboud
JL Liesveld
CH Packman
S Eberly
RF Raubertas
BA Martin
WR Flesher
PA Kouides
JF DiPersio
JM Rowe
Bone Marrow Transplantation, 1997, 19 : 883 - 890
[33] Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors
Rapoport, AP
Lifton, R
Constine, LS
Duerst, RE
Abboud, CN
Liesveld, JL
Packman, CH
Eberly, S
Raubertas, RF
Martin, BA
Flesher, WR
Kouides, PA
DiPersio, JF
Rowe, JM
BONE MARROW TRANSPLANTATION, 1997, 19 (09) : 883 - 890
[34] Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Davids, Matthew S.
Roberts, Andrew W.
Kenkre, Vaishalee P.
Wierda, William G.
Kumar, Abhijeet
Kipps, Thomas J.
Boyer, Michelle
Salem, Ahmed Hamed
Pesko, John C.
Arzt, Jennifer A.
Mantas, Margaret
Kim, Su Y.
Seymour, John F.
CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4690 - 4695
[35] Tailored therapy for aggressive non-Hodgkin's lymphoma: Results of a phase II study with a long-term follow-up
Palmieri, G
Morabito, A
Rea, A
Biondi, E
Lauria, R
Matano, E
Pagliarulo, C
Montesarchio, V
Tagliaferri, P
Bianco, AR
INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 13 (01) : 121 - 127
[36] Long-term follow-up of pathologic stage I large cell non-Hodgkin's lymphoma patients after primary radiotherapy
Lee, CK
Levitt, SH
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (02): : 93 - 98
[37] Aggressive follow-up of patients with Non-Hodgkin's lymphoma: What is optimal?
Tompkins, KA
Dryver, ET
Imrie, KR
BLOOD, 2001, 98 (11) : 235B - 235B
[38] LONG TERM FOLLOW-UP OF ADVANCED HODGKIN LYMPHOMA TREATED WITH BEACOPP REGIMEN - A SINGLE INSTITUTION EXPERIENCE
Mihaljevic, B.
Antic, D.
Jakovic, L. R.
Andjelic, B.
Tomin, D.
Petrovic, M.
HAEMATOLOGICA, 2010, 95 : S22 - S23
[39] Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).
Morris, E
Thomson, K
Craddock, C
Milligan, D
Smith, GM
Parker, A
Schey, S
Winfield, D
Chopra, R
Littlewood, T
Tighe, J
Hunter, A
Kyriakou, C
Kottaridis, P
Peggs, K
Linch, D
Goldstone, A
Mackinnon, S
BLOOD, 2002, 100 (11) : 40A - 40A
[40] A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant
J Ph Laporte
M Yeshurun
L Fouillard
M Labopin
C Cailliot
S Lesage
F Isnard
A Najman
N-C Gorin
Leukemia, 2004, 18 : 1717 - 1721

← 1 2 3 4 5 →